Patents by Inventor Mark Alfonso
Mark Alfonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9259397Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.Type: GrantFiled: October 23, 2001Date of Patent: February 16, 2016Assignee: Purdue Pharma L.P.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20150182474Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: August 12, 2014Publication date: July 2, 2015Applicant: PURDUE PHARMA L.P.Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Patent number: 8496960Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2002Date of Patent: July 30, 2013Assignee: Purdue Pharma L.P.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20080262284Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: June 27, 2008Publication date: October 23, 2008Applicant: PURDUE PHARMA L.P.Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Patent number: 7018649Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.Type: GrantFiled: October 23, 2001Date of Patent: March 28, 2006Assignee: Euro-Celtique, S.A.Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20050064022Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2002Publication date: March 24, 2005Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20050031678Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: September 20, 2004Publication date: February 10, 2005Applicant: Euro-Celtique S.AInventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
-
Publication number: 20040146547Abstract: The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.Type: ApplicationFiled: November 20, 2003Publication date: July 29, 2004Inventors: Geraldine Marcenyac, Mark Alfonso, Lane Gehrlein, Stephen Howard, Lino Tavares, Ronald Greenbaum, Seth Levy, Benjamin Oshlack
-
Patent number: 6642275Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: GrantFiled: August 16, 2001Date of Patent: November 4, 2003Assignee: Euro- Celtique, S.A.Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler
-
Publication number: 20030072791Abstract: A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2001Publication date: April 17, 2003Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20030035828Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.Type: ApplicationFiled: October 23, 2001Publication date: February 20, 2003Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20020198215Abstract: A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.Type: ApplicationFiled: October 23, 2001Publication date: December 26, 2002Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti H. Valia
-
Publication number: 20020022663Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: ApplicationFiled: August 16, 2001Publication date: February 21, 2002Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler
-
Publication number: 20010049391Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: ApplicationFiled: November 5, 1999Publication date: December 6, 2001Inventors: MARK ALFONSO, PAUL GOLDENHEIM, RICHARD SACKLER
-
Patent number: 6017963Abstract: A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.Type: GrantFiled: November 14, 1995Date of Patent: January 25, 2000Assignee: Euro-Celtique, S.A.Inventors: Mark Alfonso, Paul Goldenheim, Richard Sackler